Literature DB >> 18028420

Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.

Mathieu Capovilla1, Jean-Michel Cayuela, Chrystèle Bilhou-Nabera, Claude Gardin, Remi Letestu, Fanny Baran-Marzak, Pierre Fenaux, Antoine Martin.   

Abstract

Several reports of successful empirical treatment of idiopathic hypereosinophilic syndrome with imatinib led to the recent identification of the FIP1L1-PDGFRA fusion gene rearrangement, which characterizes a distinctive group of chronic eosinophilic leukemias. This fusion gene can be detected in eosinophils, neutrophils, mast cells, T cells, B cells and monocytes in FIP1L1-PDGFRA-positive hypereosinophilic patients suggesting a multilineage involvement. Furthermore, the same FIP1L1-PDGFRA rearrangement was identified in patients with hypereosinophilia and atypical mast cell proliferations, raising the question of a disease with two concomitant lines of differentiation. In addition, a recent report noted two cases with the association of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma (T-LBL). We report here the only third case of synchronous chronic eosinophilic leukemia and T-LBL, both associated with a FIP1L1-PDGFRA fusion transcript, confirming the occurrence of such disease and suggesting a clonal proliferation with two lines of differentiation probably arising from a primitive multipotent medullary stem cell.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028420     DOI: 10.1111/j.1600-0609.2007.00973.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes.

Authors:  Hung Chang; Wen-Yu Chuang; Chien-Feng Sun; Marc R Barnard
Journal:  Diagn Pathol       Date:  2012-02-22       Impact factor: 2.644

Review 3.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

4.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

Review 5.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113

6.  T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Authors:  Grzegorz Helbig; Agata Wieczorkiewicz; Joanna Dziaczkowska-Suszek; Miroslaw Majewski; Slawomira Kyrcz-Krzemien
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

7.  Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review.

Authors:  Xiaorui Fu; Yufeng Shang; Lei Zhang; Ling Li; Xin Li; Xinhua Wang; Zhenchang Sun; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.